---
title: "Vericel Corporation (VCEL.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/VCEL.US.md"
symbol: "VCEL.US"
name: "Vericel Corporation"
industry: "Biotechnology"
datetime: "2026-05-19T17:14:23.253Z"
locales:
  - [en](https://longbridge.com/en/quote/VCEL.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/VCEL.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/VCEL.US.md)
---

# Vericel Corporation (VCEL.US)

## Company Overview

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.vcel.com](https://www.vcel.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: B (0.26)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 34 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 22.45% |  |
| Net Profit YoY | 620.69% |  |
| P/B Ratio | 5.00 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1780749110.36 |  |
| Revenue | 292086000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 6.59% | C |
| Profit Margin | 7.35% | B |
| Gross Margin | 72.00% | A |
| Revenue YoY | 22.45% | A |
| Net Profit YoY | 620.69% | A |
| Total Assets YoY | 14.38% | B |
| Net Assets YoY | 20.56% | A |
| Cash Flow Margin | 287.45% | A |
| OCF YoY | 22.45% | A |
| Turnover | 0.64 | B |
| Gearing Ratio | 26.65% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Vericel Corporation",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "22.45%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "620.69%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "5.00",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1780749110.36",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "292086000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "6.59%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "7.35%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "72.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "22.45%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "620.69%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "14.38%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "20.56%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "287.45%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "22.45%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.64",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "26.65%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 82.97 | 58/386 | 597.42 | 155.60 | 110.42 |
| PB | 5.00 | 325/386 | 6.34 | 5.83 | 5.09 |
| PS (TTM) | 6.10 | 126/386 | 7.89 | 7.25 | 6.40 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-12T04:00:00.000Z

Total Analysts: **8**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 7 | 88% |
| Hold | 1 | 13% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 35.19 |
| Highest Target | 64.00 |
| Lowest Target | 42.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/VCEL.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/VCEL.US/norm.md)
- [Related News](https://longbridge.com/en/quote/VCEL.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/VCEL.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**